Should New HEPZATO Subgroup Data and Delcath’s Targeted Strategy Require Action From DCTH Investors?

Delcath Systems announced that subgroup analyses from its phase 3 FOCUS study of the FDA-approved HEPZATO KIT for unresectable metastatic uveal melanoma were published in the Journal of Cancer ...
Denver7

Colorado flu hospitalizations surge to record levels after holiday gatherings

Nearly 2,500 people have been hospitalized with influenza in Colorado since October, and recent holiday celebrations are now ...